| Synonym |
| Thai / English name |
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : ethanolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : The inhibitory activity on CYP2C19, mean IC50 of the selective inhibitor nootkatone was 5.64 microgram/mL. The inhibitory activities of PI and DM were classified in the most potent group with potency comparable to that of nootkatone (mean IC50 4.71 and 6.92 microgram/mL, respectively, p > 0.05). PC, DL, MF, AL and ZO exhibited moderate potencies (mean IC50 10.44-17.06 microgram/mL), while GM exhibited the lowest potency (mean IC50 61.75 microgram/mL) (Substrate: Omeprazole)Note : Piper chaba (PC), Dioscroea membranacea (DI), Dracaenal oureiri (DG), Atractylodes lancea (AL), Plumbago indica (PI), Zingiber officinale (ZO), Myristica fragrans (MF), Garcinia mangostana (GM).
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : ethanolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : The selective inhibitor quinidine showed the most potent inhibitory activity on CYP2D6 activity with mean IC50 of 0.97 microgram/mL. DM, DL and PI showed the highest inhibitory activities (mean IC50 2.93-9.57 microgram/mL). The potency of inhibitory activity of DM was comparable to that of quinidine (p > 0.05). PC, GM and ZO exhibited moderate potencies (mean IC50 23.40-31.32 microgram/mL), and MF and AL exhibited relatively low potencies (mean IC50 195.83 and 313.51 microgram/mL, respectively). (substrate: extromethorphan)Note : Piper chaba (PC), Dioscroea membranacea (DI), Dracaenal oureiri (DG), Atractylodes lancea (AL), Plumbago indica (PI), Zingiber officinale (ZO), Myristica fragrans (MF), Garcinia mangostana (GM).
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : ethanolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : The selective inhibitor ketoconazole showed the most potent inhibitory activity on CYP3A4 with mean IC50 of 0.23 microgram/mL. PC, DM, DL, PI were most potent with mean IC 1.54-6.43 microgram/mL. PC exhibited similar inhibitory activity to ketoconazole (p > 0.05). GM and ZO exhibitied moderate potencies (mean IC50 11.33 and 11.58 microgram/mL, respectively). MF and AL exhibited relatively low potencies (mean IC50 41.91 and 54.36 microgram/mL, respectively) (substrate:nifedipine)Note : Piper chaba (PC), Dioscroea membranacea (DI), Dracaenal oureiri (DG), Atractylodes lancea (AL), Plumbago indica (PI), Zingiber officinale (ZO), Myristica fragrans (MF), Garcinia mangostana (GM).
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 60 (M/F=47/13)N(Treatment) : 30 (M/F=22/8)Sex : Both sexAge : 37.3 +/-11.01 yearsRoute : Oral administrationDose/Conc.(herb) : 500 mg (two capsules orally), 30 min before morning anti-TB medicationsDuration : 4 weeksType of interaction : PharmacokineticsInteraction with drug : Isoniazid*/Isonicotinylhydrazide/Isonicotinic acid hydrazide/INHDose/Conc.(drug) : 5 mg/kg/dayResult : PositiveRemark : This preliminary trial supports the role of ginger in the prevention of antituberculosis (TB)-induced gastrointestinal ADRs including nausea and vomiting. The results weakly support the role of ginger in the prevention of anti-TB induced hepatotoxicity.Note : Subjects: patients with tuberculosis were divided into ginger group (n=30) or placebo group (n=30, M/F=25/5). Dose: each capsule containing 250 mg standard powdered rhizome of ginger. Drug: anti-TB drugs including isonicotinylhydrazide (lNH) (5 mg/kg/day), rifampin (RlF) (10 mg/kg/day), ethambutol (15 mg/kg/day), and pyrazinamide (PZA) (25 mg/kg/day) were administered as once daily dose.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 60 (M/F=47/13)N(Treatment) : 30 (M/F=22/8)Sex : Both sexAge : 37.3 +/-11.01 yearsRoute : Oral administrationDose/Conc.(herb) : 500 mg (two capsules orally), 30 min before morning anti-TB medicationsDuration : 4 weeksType of interaction : PharmacokineticsInteraction with drug : Rifampicin*/RifampinDose/Conc.(drug) : 10 mg/kg/dayResult : PositiveRemark : This preliminary trial supports the role of ginger in the prevention of antituberculosis (TB)-induced gastrointestinal ADRs including nausea and vomiting. The results weakly support the role of ginger in the prevention of anti-TB induced hepatotoxicity.Note : Subjects: patients with tuberculosis were divided into ginger group (n=30) or placebo group (n=30, M/F=25/5). Dose: each capsule containing 250 mg standard powdered rhizome of ginger. Drug: anti-TB drugs including isonicotinylhydrazide (lNH) (5 mg/kg/day), rifampin (RlF) (10 mg/kg/day), ethambutol (15 mg/kg/day), and pyrazinamide (PZA) (25 mg/kg/day) were administered as once daily dose.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 60 (M/F=47/13)N(Treatment) : 30 (M/F=22/8)Sex : Both sexAge : 37.3 +/-11.01 yearsRoute : Oral administrationDose/Conc.(herb) : 500 mg (two capsules orally), 30 min before morning anti-TB medicationsDuration : 4 weeksType of interaction : PharmacokineticsInteraction with drug : Ethambutol*/EthambutolumDose/Conc.(drug) : 15 mg/kg/dayResult : PositiveRemark : This preliminary trial supports the role of ginger in the prevention of antituberculosis (TB)-induced gastrointestinal ADRs including nausea and vomiting. The results weakly support the role of ginger in the prevention of anti-TB induced hepatotoxicity.Note : Subjects: patients with tuberculosis were divided into ginger group (n=30) or placebo group (n=30, M/F=25/5). Dose: each capsule containing 250 mg standard powdered rhizome of ginger. Drug: anti-TB drugs including isonicotinylhydrazide (lNH) (5 mg/kg/day), rifampin (RlF) (10 mg/kg/day), ethambutol (15 mg/kg/day), and pyrazinamide (PZA) (25 mg/kg/day) were administered as once daily dose.
Part Used : เหง้าActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : Double-blind trialN(Total) : 60 (M/F=47/13)N(Treatment) : 30 (M/F=22/8)Sex : Both sexAge : 37.3 +/-11.01 yearsRoute : Oral administrationDose/Conc.(herb) : 500 mg (two capsules orally), 30 min before morning anti-TB medicationsDuration : 4 weeksType of interaction : PharmacokineticsInteraction with drug : Pyrazinamide*/Pyrazinecarboxamide/Pyrazinoic acid amideDose/Conc.(drug) : 25 mg/kg/dayResult : PositiveRemark : This preliminary trial supports the role of ginger in the prevention of antituberculosis (TB)-induced gastrointestinal ADRs including nausea and vomiting. The results weakly support the role of ginger in the prevention of anti-TB induced hepatotoxicity.Note : Subjects: patients with tuberculosis were divided into ginger group (n=30) or placebo group (n=30, M/F=25/5). Dose: each capsule containing 250 mg standard powdered rhizome of ginger. Drug: anti-TB drugs including isonicotinylhydrazide (lNH) (5 mg/kg/day), rifampin (RlF) (10 mg/kg/day), ethambutol (15 mg/kg/day), and pyrazinamide (PZA) (25 mg/kg/day) were administered as once daily dose.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : humanType of animal : -Type of study : non specifiedN(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : Ginger fraction, use thereof on its own or combined with drugs for inhibiting human cytochrome P450 (CYP) enzymes (particularly cytochrome P 450 3A4, CYP3A4) for positive influencing the oral bioavailablity and pharmacokinetics of active substance.Note : Data incomplete from abstract
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Ginger extract 25 mgDuration : -Type of interaction : PharmacokineticsInteraction with drug : SimvastatinDose/Conc.(drug) : 20 mgResult : PositiveRemark : A capsule formulation was obtained by combining 41.3 mg delayed-release simvastatin pellets (simvastatin dose 20 mg), as a drug transporter substrate, with 75 mg of pellets containing ginger extract (ginger extract dose 25 mg).Note : Data incomplete
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : 6-gingerolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : capsaicin, curcumin, [6]-gingerol, and resveratrol, have inhibitory effects on P-glycoprotein and potencies to cause drug-food interactionsNote : Data incomplete
